New York, February 23, 2026, 11:01 (EST) — Regular session
- Eli Lilly shares climbed roughly 4% in the morning, easily outperforming a weaker U.S. market.
- Novo Nordisk’s new obesity drug, CagriSema, fell short against Lilly’s tirzepatide in direct comparison, the company said.
- Lilly highlighted new FDA approval for a four-dose Zepbound pen, targeting self-pay patients.
Eli Lilly and Co (LLY) climbed roughly 4.0% to $1,049.85 Monday morning, with investors reacting after Novo Nordisk’s latest obesity drug didn’t outperform Lilly’s tirzepatide in direct testing.
This is significant: obesity drugs are the main engine behind large pharma’s valuations these days. So when a rare head-to-head study tips the scales, traders often see it as an indicator for market share, not just another clinical data point.
This comes as investors puzzle over just how durable the “best-in-class” edge really is in weight loss, especially if payers start leaning harder on pricing. The discussion’s been heated for months. A head-to-head comparison only amplifies it.
Novo reported its CagriSema drug trimmed patient weight by 23% over 84 weeks. Lilly’s tirzepatide, marketed as Zepbound for obesity, delivered a 25.5% reduction in the same period. This was based on an open-label study of about 800 participants, so everyone knew which medication they were getting. Novo’s chief scientific officer admitted he was “little bit surprised” by how Zepbound performed. A Union Investment shareholder, who holds Novo and Lilly shares, didn’t mince words, calling the outcome “a worst-case scenario for Novo.” From Nordnet’s analyst: “to investors it’s very significant.” Reuters
Lilly announced the U.S. Food and Drug Administration has signed off on a label expansion for Zepbound, clearing the way for a four-dose KwikPen. That device covers a month’s worth of weekly shots in one pen. All doses, whether through the multi-dose pen or a single-dose vial, will be available to self-pay patients using LillyDirect at the same price. The starting point: $299 a month for the 2.5 mg dose. “Zepbound is the #1 prescribed injectable obesity‑management medication,” Lilly executive vice president Ilya Yuffa said. Finviz
Lilly shares surged even as the broader market slipped. U.S. equities retreated, weighed down by new tariff worries after President Donald Trump set a fresh 15% duty. One market watcher summed up sentiment bluntly: “You simply can’t bet against Trump.” Reuters
The obesity-drug trade remains unpredictable. Fresh data, a shift in pricing, or changes to coverage can send expectations zigzagging in a hurry — both major players have a lot riding on ambitious growth and durability bets.
Traders now turn to see if the new pen format drives more demand through LillyDirect and makes things smoother for self-pay patients. Novo, for its part, aims to reshape the narrative after its miss, with more studies in the pipeline. Everyone’s also waiting for any news on supply updates and how strict pricing will get as the competitive pressure increases.
Investors will be watching April 30, when Lilly reports earnings, for updates on Zepbound—access, demand, and where management says the competition stands.
